Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06236815 · ClinicalTrials.gov registry record · Early Phase 1

High Confusion: Cannabis & Driving

A Early Phase 1 study, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Early Phase 1
Development phase
5
Enrollment target

NCT06236815: Completed Early Phase 1 study, sponsored by University of Wisconsin, Madison.

NCT06236815 is a Early Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 5 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06236815, a Early Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Early Phase 1
Development phase
5 participants
Enrollment target

Study Summary

This study is being done to assess the feasibility of administrating Δ9-THC and Δ8-THC isolates and simultaneously adopting several data harmonization measures to generate uniquely translatable data. This project aims to (1) evaluate the feasibility and acceptability of administering ∆9-THC and Δ8-THC isolates using standardized cannabis dosing units to quantify ∆9-THC and Δ8-THC pharmacokinetics; and (2) evaluate the feasibility and acceptability of adopting standardized impairment detection methods and driving performance definitions and measures on quantifying ∆9-THC and Δ8-THC driving impairment compared to a placebo.

Primary Outcome

Quantify delta-9-THC, delta-8-THC, and their primary metabolites in whole blood, plasma, oral fluid, and dried blood spots at several time points before and after acute study drug administration.

Interventions

  • DRUG Placebo
  • DRUG Delta-9-THC
  • DRUG Delta-8-THC

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2025-01-25
Est. Completion 2025-09-16
Phase Early Phase 1
University of Wisconsin, Madison

1,039 total trials

What the finished NCT06236815 record still lists

NCT06236815 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT06236815 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06236815 about?

NCT06236815 is a clinical study titled "High Confusion: Cannabis & Driving". This study is being done to assess the feasibility of administrating Δ9-THC and Δ8-THC isolates and simultaneously adopting several data harmonization measures to generate uniquely translatable data. This project aims to (1) evaluate the feasibility and acceptability of administering ∆9-THC and Δ8-T...

What is the current status of trial NCT06236815?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2025-01-25. Estimated completion is 2025-09-16.

What interventions are being tested in trial NCT06236815?

The interventions under investigation include: Placebo (DRUG), Delta-9-THC (DRUG), Delta-8-THC (DRUG).

Who is sponsoring clinical trial NCT06236815?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06236815's enrollment target sits among peer trials

5 1888th of 2000 higher than 80 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06236815, the US trial registry maintained by the National Library of Medicine. NCT06236815 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.